Accéder au contenu
Merck

RALGA (Diacneal), a retinaldehyde and glycolic acid association and postinflammatory hyperpigmentation in acne--a review.

Dermatology (Basel, Switzerland) (2005-02-23)
A D Katsambas
RÉSUMÉ

Acne vulgaris affects 3 out of 4 adolescents and usually vanishes at the end of puberty with either no sequelae or mild to moderate sequelae, such as postinflammatory hyperpigmenation (PIH), which may result in psychological and emotional damages. The poor tolerability of the actual treatments (secondary inflammation) is a hindrance to therapy. Retinaldehyde (RAL), a precursor of retinoic acid, has shown depigmenting activity. Glycolic acid (GA) decreases the excess of pigment by a wounding and re-epithelization process. Thus, a synergistic effect was expected from the combination of RAL 0.1% and GA 6% RALGA (Diacneal) in the treatment of acne vulgaris and PIH. Efficacy results of preclinical and clinical trials tend to confirm the expectations for both acne and PIH treatment. A good tolerability was observed. In conclusion, the cosmetic cream Diacneal is a well-tolerated treatment for the prevention and healing of PIH in acne patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Glycolic acid, ReagentPlus®, 99%
Sigma-Aldrich
Glycolic acid solution, technical grade, 70 wt. % in H2O
Sigma-Aldrich
Glycolic acid solution, high purity, 70 wt. % in H2O
Supelco
Glycolic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycolic acid, BioXtra, ≥98.0% (titration)
Supelco
Glycolic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland